OTCM
PSYGF
Market cap1mUSD
Oct 09, Last price
0.11USD
Name
Psyence Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-400k
L-99.42%
CFO
-6m
L+12.87%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Psyence Group Inc. is a biotechnology firm operating in the life sciences sector, primarily focused on the commercial cultivation and production of psilocybin mushrooms. The company's naturally derived psilocybin is intended for therapeutic applications, targeting a variety of mental health conditions and other medical ailments. Currently, Psyence Group Inc. is engaged in formulating pharmaceutical-grade psilocybin dosages aimed at alleviating psychological trauma and specific diagnosable disorders, such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress associated with grief and bereavement. Furthermore, the company develops, distributes, and markets over-the-counter functional mushroom nutraceuticals, which are free of psilocybin, under its GOODMIND brand. Founded in 2019, Psyence Group Inc. is based in Toronto, Canada.
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |